CD27
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
CD27 is a member of the tumor necrosis factor receptor superfamily. It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule, and is the target of an anti-cancer drug in clinical trials.
CD27 is a member of the tumor necrosis factor receptor superfamily. It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule, and is the target of an anti-cancer drug in clinical trials. ==Clinical significance== ===As a drug target=== Varlilumab is an IgG1 antibody that binds to CD27 and is an experimental cancer treatment. This agonist antibody stimulates CD27 when it binds. The drug is in early clinical trials and appears to stimulate T cells and increase production of cytokines such as interferon-gamma.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1313891536 under CC BY-SA 4.0; modifications have been made.